|
Atazanavir/RTV/Emtricitabine/Tenofovir
vs Elvitegravir/Cobicistat/Emtricitabine/Tenofovir
|
| |
Development and Validation of an Assay to Analyze Atazanavir in
Human Hair Via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
Phung N, Kuncze K, Okochi H,
et al
Rapid Commun Mass Spectrom. 2018
Jan 9.
Abstract
Is the unbound concentration of Atazanavir of interest in
Therapeutic Drug Monitoring?
Metsu D, Seraissol P, Delobel P,
et al
Fundam Clin Pharmacol. 2016 Sep
24.
Abstract
Cerebrospinal fluid analysis for HIV replication and biomarkers
of immune activation and neurodegeneration in long-term atazanavir/ritonavir
monotherapy treated patients.
Ferretti F, Bigoloni A,
Passeri L, et al
Medicine (Baltimore). 2016 Jul;95(28):e4144.
Abstract
Quantitative determination of free/bound atazanavir via
high-throughput equilibrium dialysis and LC-MS/MS, and the application in ex
vivo samples.
Xu XS, Rose A, Demers R, et al
Bioanalysis. 2014 Dec;6(23):3169-82.
Abstract
Quantification of cell-associated atazanavir, darunavir,
lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell
extracts.
Podany AT, Winchester LC, Robbins BL, Fletcher CV.
Antimicrob Agents Chemother. 2014 May;58(5):2866-70
Abstract
Validation of Simultaneous Quantitative Method of HIV Protease
Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS.
Mishra T, Shrivastav PS.
ScientificWorldJournal.
2014 Jan 23;2014:482693.
Abstract
Atazanavir-Induced Urine Crystals Demonstrated by Infrared
Spectroscopic Analysis.
Inagaki I, Adachi M, Ito H, et al
Urol Int. 2013 Dec 5
Abstract
External Validation of the Bilirubin-Atazanavir
Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected
Patients.
Rekić D, Röshammar D, Bergstrand M, et al
AAPS J.
2012 Dec 7.
Abstract
Comparison of extraction procedures for assessment of matrix effect
for selective and reliable determination of atazanavir in human plasma
by LC-ESI-MS/MS.
Yadav M, Trivedi V, Upadhyay V,
J Chromatogr B Analyt Technol Biomed Life Sci. 2012
Jan 9.
Abstract |
Limited sampling strategies for the estimation of
atazanavir daily exposure in HIV-infected patients.
Cattaneo D, Ripamonti D, Baldelli
Fundam Clin Pharmacol.
2011 Nov 2. .
Abstract |
UPLC-MS/MS quantification of nanoformulated ritonavir,
indinavir, atazanavir, and efavirenz in
mouse serum and tissues.
Huang J, Gautam N, Bathena SP
JChromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 1
Abstract
Therapeutic Monitoring and Variability of Atazanavir in HIV-Infected
Patients, With and Without HCV Coinfection, Receiving Boosted or Unboosted Regimens.
Regazzi M, Villani P, Gulminetti R, et al
Ther Drug Monit.
2011 May 4.
Abstract
Use of serum bilirubin levels as surrogate marker of early virological
response to atazanavir-based
antiretroviral therapy.
Morello J, Alvarez E, Cuenca L,
et al
AIDS Res Hum Retroviruses.
2011 Feb 25.
Abstract
Clinical Evaluation of a Dried Blood Spot Assay for
Atazanavir
Van Schooneveld T, Swindells S,
Nelson SR, et al
Antimicrob Agents Chemother. 2010
Jul 26.
Abstract |
The relation between treatment outcome and efavirenz, atazanavir or
lopinavir
exposure in the NORTHIV trial of treatment-naďve HIV-1 infected
patients.
Josephson F, Andersson MC, Flamholc L, et al
Eur J Clin Pharmacol.
2009 Dec 5.
Abstract |
|
Baseline lipid levels rather than the presence of reported body shape
changes determine
the degree of improvement in lipid levels after switching to atazanavir.
van Vonderen, Gras, Wit, Brinkman, et al
HIV
Clin Trials.
2009 May-Jun;10(3):168-80.
Abstract
|
|
|
|
| |
Long-term oral atazanavir attenuates myocardial infarction-induced cardiac
fibrosis.
Zhang G, Zhang X, Li D, Tian J, Jiang W.
Eur J Pharmacol. 2018 Mar 29
Abstract
Inflammation investigated as a source of pharmacokinetic variability of
atazanavir in AIDS Clinical Trials Group protocol A5224s.
Venuto CS, Lim J, Messing S, et
al
Antivir Ther. 2017
Nov 24.
Abstract
Ureteral Obstruction Due to Radiolucent Atazanavir Ureteral Stones.
Grant MT, Eisner BH, Bechis SK.
J Endourol Case Rep. 2017
Oct 1;3(1):152
Abstract
Atazanavir-Associated Crystalline Nephropathy.
Santoriello D, Al-Nabulsi M, Reddy A,
et al
Am J Kidney Dis. 2017 Jun
2
Abstract
Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience
With Atazanavir.
Roy-Chowdhury J, Roy-Chowdhury N,
et al
Clin Pharmacol Drug Dev. 2017
Mar;6(2):140-146
Abstract
Psychiatric Symptoms in Patients Receiving Dolutegravir.
Fettiplace A, Stainsby C, Winston A,
et al
J Acquir Immune Defic Syndr.
2016 Dec 7.
Abstract
Acute intermittent porphyria precipitated by
atazanavir/ritonavir.
Bharti S, Malhotra P, Hirsch B.
Int J STD AIDS.
2016 Nov;27(13):1234-1235.
Abstract
FULL-TEXT ARTICLE
Risk of cardiovascular events among patients with HIV treated with
atazanavir-containing regimens: a retrospective cohort study.
Rosenblatt L, Farr AM, Nkhoma ET, Nelson JK,
et al
BMC Infect Dis. 2016 Sep 19;16(1):492.
Paper
Frequency of atazanavir-associated leukocyturia development and
renal function decline.
Dbeibo L, Arif S, He F, Gupta SK.
AIDS. 2016 Jun 1;30(9):1488-9.
Abstract
Severe hyperbilirubinemia in an HIV-HCV coinfected patient
starting the 3D regimen that resolved after TDM-guided atazanavir dose
reduction.
Cattaneo D, Riva A, Clementi E,
et al
Ther Drug Monit. 2016 Feb 25.
Abstract
Atazanavir use and carotid intima media thickness progression in
HIV: potential influence of bilirubin.
Chow D, Kohorn L, Souza S, Ndhlovu L,
AIDS. 2016 Feb
20;30(4):672-4
Abstract
Acute intermittent porphyria precipitated by atazanavir/ritonavir.
Bharti S, Malhotra P, Hirsch B.
Int J STD AIDS. 2016 Feb 11. pii:
0956462416633981
Abstract
Clinical Pharmacogenetics Implementation Consortium (CPIC)
Guideline for UGT1A1 and Atazanavir Prescribing.
Gammal RS, Court MH, Haidar CE, et al
Clin Pharmacol Ther. 2015 Sep 29.
Abstract
FULL-TEXT ARTICLE
Relationships
between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis
Marinescu CI, Leyes M, Ribas MA, et al
AIDS Res Treat. 2015;2015:
Paper
FULL-TEXT ARTiCLE
Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in
HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
Gervasoni C, Meraviglia P, Minisci D,
et al
PLoS One. 2015 Apr
15;10(4):e0123670.
Paper
FULL-TEXT ARTiCLE
Atazanavir
nephrotoxicity.
Hara M, Suganuma A, Yanagisawa N,
et al
Clin Kidney J. 2015 Apr;8(2):137-42.
Paper
Changes in kidney function in patients with suppressed HIV RNA
who substitute their protease inhibitor with atazanavir/ritonavir.
Hamzah L, Campbell L, Wandolo E,
et al
AIDS. 2015 Jan 28;29(3):392-4.
Abstract
Immune reconstitution in severely immunosuppressed
antiretroviral-naive HIV-1-infected patients starting efavirenz,
lopinavir-ritonavir, or atazanavir-ritonavir plus tenofovir/emtricitabine: Final
48-week results (the Advanz-3 trial).
Miro JM, Manzardo C, Ferrer E, et al
J Acquir Immune Defic Syndr.
2015 Feb 17.
Abstract
Iatrogenic Cushing's syndrome after triamcinolone plus
ritonavir-boosted atazanavir.
Jakeman
B, Conklin J, Bouchonville M, Thornton K.
J Am Pharm Assoc (2003).
2015 Feb 6:e87-e
Abstract
Pharmacogenetic testing can identify patients taking atazanavir
at risk for hyperbilirubinaemia.
Avihingsanon A, Tongkobpetch S, Kerr SJ, et al
J Acquir Immune Defic Syndr. 2015 Jan
23.
Abstract
Atherogenic properties of lipoproteins in HIV patients starting
atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR
randomized study.
Saumoy M, Ordóńez-Llanos J, Martínez E, et al
J Antimicrob Chemother. 2014 Dec 23.
Abstract
FULL-TEXT ARTICLE
Clinical Features and Risk Factors for Atazanavir (ATV)-Associated Urolithiasis:
A Case-Control Study
Lafaurie M, De Sousa B, Ponscarme D, et al
PLoS One. 2014 Nov
19;9(11):e112836.
Paper
Changes in bone mineral density after 96 weeks of treatment with
atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir
DF/emtricitabine in treatment-naďve patients with HIV-1 infection: The CASTLE
body composition substudy.
Moyle G, Hardy H, Farajallah A, et al
J Acquir Immune Defic Syndr. 2014 Oct 7
Abstract
Single-nucleotide polymorphisms in the
UDP-glucuronosyltransferase 1A-3' untranslated region are associated with
atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a
pharmacogenetic study.
Nishijima T, Tsuchiya K, Tanaka N,
et al
J Antimicrob Chemother. 2014 Aug 23.
Abstract
Genomewide association study of atazanavir
pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol
A5202.
Johnson DH, Venuto C, Ritchie MD,
Pharmacogenet Genomics. 2014 Feb 19.
Abstract
Investigation on the mechanism for the
binding and drug resistance of wild type and mutations
of G86 residue in HIV-1 protease complexed with
Darunavir by molecular dynamic simulation and free
energy calculation.
Li D, Zhang Y, Zhao RN,
et
al
J Mol Model.
2014 Feb;20(2):2122.
Abstract
Impact of darunavir, atazanavir and lopinavir boosted with
ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
Auclair M, Afonso P, Capel E, et al
Antivir Ther. 2014 Feb 17
Abstract
Early lipid changes with atazanavir/ritonavir or
darunavir/ritonavir.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, et al
HIV Med. 2014 Jan 12.
Abstract
Recurrent nephrolithiasis associated with atazanavir use.
Wang LC, Osterberg EC, David SG, Rosoff JS.
BMJ Case Rep. 2014 Jan 8;2014.
Abstract
Cumulative exposure to ritonavir-boosted atazanavir is associated
with cholelithiasis in patients with HIV-1 infection.
Nishijima T, Shimbo T, Komatsu H, et al
J Antimicrob Chemother. 2013 Dec 29
Abstract
Atazanavir-Induced Urine Crystals Demonstrated by Infrared
Spectroscopic Analysis.
Inagaki I, Adachi M, Ito H, et al
Urol Int. 2013 Dec 5
Abstract
Atazanavir and chest pain.
Phillips M, Saxon C, Lee V.
Int J STD AIDS. 2013
Oct 9.
Abstract
FULL-TEXT ARTICLE
Is
ritonavir-boosted atazanavir a risk for cholelithiasis compared to other
protease inhibitors?
Hamada Y, Nishijima T, Komatsu H, et al
PLoS
One. 2013 Jul 16;8(7):e69845
Paper
Atazanavir and Other Determinants of Hyperbilirubinemia in a
Cohort of 1150 HIV-Positive Patients: Results from 9 Years of Follow-Up.
Laprise C, Baril JG, Dufresne S, Trottier H.
AIDS Patient Care STDS. 2013 Jul;27(7):378-86.
Abstract
Co-administration of atazanavir/ritonavir and zinc sulphate: impact on
hyperbilirubinemia and pharmacokinetics.
Moyle G, Else L, Jackson A,
et al
Antimicrob Agents Chemother.
2013 May 20.
Abstract
Atazanavir induced first degree atrioventricular block and
ventricular tachycardia: a case report.
Santimaleeworagun W, Pattharachayakul S, Chusri S, Chayagul P.
J Med Assoc Thai. 2013
Apr;96(4):501-3
Abstract
Predictors of the change in bilirubin levels over twelve weeks
of treatment with atazanavir.
Cotter AG, Brown A, Sheehan G,
et al
AIDS Res Ther. 2013 May 16;10(1):13.
Abstract
Effect of the UGT1A1*28 Allele on Unconjugated
Hyperbilirubinemia in HIV-Positive Patients Receiving Atazanavir: A Systematic
Review (April).
Culley CL, Kiang TK, Gilchrist SE, Ensom MH.
Ann Pharmacother. 2013 Apr 2. [
Abstract |
Atazanavir is not associated with an increased risk of cardio
or cerebrovascular disease events.
Monforte AD, Reiss P, Ryom L, et al
AIDS. 2013 Jan 28;27(3):407-415.
Abstract |
Role of Drug Efflux and Uptake Transporters in Atazanavir
Intestinal Permeability and Drug-Drug Interactions.
Kis O, Zastre JA,
Hoque MT, et al
Pharm Res. 2012 Dec 7.
Abstract
High incidence of renal stones in HIV-infected patients on ritonavir-boosted
atazanavir than in those on other protease inhibitors-containing
antiretroviral therapy.
Hamada Y, Nishijima T, Watanabe K, Komatsu H, et al
Clin Infect Dis. 2012 Jul 19.
Abstract
Complicated Atazanavir-associated Cholelithiasis: a Report of 14 Cases.
Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al
Clin Infect Dis. 2012 Jul 19
Abstract
Diffuse Tubulointerstitial Nephritis Accompanied by Renal Crystal Formation in
an HIV-infected Patient Undergoing
Highly Active Antiretroviral Therapy.
Kanzaki G, Tsuboi N, Miyazaki Y,
et al
Intern Med.
2012;51(12):1543-8.
Abstract |
Clinical Significance of Hyperbilirubinemia Among HIV-1-Infected
Patients Treated with Atazanavir/Ritonavir
Through 96 Weeks in the CASTLE Study.
McDonald C, Uy J, Hu W, et
al
AIDS Patient Care STDS. 2012 Mar 9.
Abstract |
Symptomatic Hyperbilirubinemia Secondary to Dapsone Induced Hemolysis and
Atazanavir Therapy.
East J, Blanton LS.
Antimicrob Agents Chemother. 2011
Nov 28.
Abstract
UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in
HIV-infected patients on HAART in southern Brazil.
Turatti L, Sprinz E, Lazzaretti RK,
et al
AIDS Res Hum Retroviruses. 2011
Nov 4
Abstract
Unexpected atazanavir-associated biliary lithiasis in an
HIV-infected patient.
Courbon E, Laylavoix F, Soulié C,
et al
J Antimicrob Chemother.
2011 Oct 23.
Abstract |
Short communication: use of serum bilirubin levels as surrogate marker of early
virological response to atazanavir-based
antiretroviral therapy.
Morello J, Alvarez E, Cuenca L,
et al
AIDS Res Hum Retroviruses. 2011
Oct;27(10):1043-5.
Abstract
Atazanavir/r exposure is associated with an increased rate of renal
stones compared with
efavirenz, lopinavir/r and darunavir/r.
Rockwood N, Mandalia S, Bower M, et al
AIDS. 2011 Jun
29.
Abstract
Development of Buffalo Hump in the course of antiretroviral therapy including
raltegravir and
unboosted atazanavir: a case report and review of the literature.
Ceccarelli G, d'Ettorre G, Marchetti F, et al
J Med Case Reports. 2011
Feb 17;5(1):70
Abstract
Chronic interstitial nephritis in an HIV type-1-infected patient
receiving ritonavir-boosted atazanavir.
Viglietti D, Verine J, De Castro N, et al
Antivir Ther.
2011;16(1):119-21.
Abstract
Impact of atazanavir-based HAART regimen on the carotid intima-media thickness
of
HIV-infected persons: a comparative prospective cohort.
de Saint-Martin L, Bressollette L,
Perfezou P, et al
AIDS.
2010 Nov 27;24(18):2797-801.
Abstract |
FULL-TEXT ARTICLE
Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV
Patients: 30 Months Follow-up Results in a Population with Low
UDP-glucuronosyltransferase1A1*28 Allele
Frequency.
Choe PG, Park WB, Song JS,
et al
J Korean Med Sci.
2010 Oct;25(10):1427-30.
Paper |
Lipid profiles in HIV-infected adults receiving atazanavir and
atazanavir/ritonavir:
systematic review and meta-analysis of randomized controlled trials.
Carey D, Amin J, Boyd M, Petoumenos K, Emery S.
J Antimicrob Chemother.
2010 Jun 16
Abstract |
Adverse Reactions of Atazanavir, Fosamprenavir and Tipranavir in "Real Life"
Balayssac E, Autret-Leca E, Jonville-Béra AP,
et al
Therapie. 2010
3-4;65(2):121-128.
Abstract |
Renal toxicity associated with tenofovir use.
Rodriguez-Nóvoa S,
Alvarez E, Labarga P, Soriano V.
Expert Opin Drug Saf.
2010 Apr 13.
Abstract |
Impact of Ritonavir, Atazanavir and their Combination on the CYP3A4
Induction Potential
of Efavirenz in Primary Human Hepatocytes.
Mugundu GM, Hariparsad N, Desai PB.
Drug Metab Lett.
2010 Mar 4.
Abstract |
Atazanavir-Associated Choledocholithiasis Leading to Acute
Hepatitis in an
HIV-Infected Adult
Jacques
AC, Gigučre P, Zhang G,
Ann Pharmacother.
2009 Dec 2
Abstract |
Hyperbilirubinemia during Atazanavir Treatment in 2,404
Patients in the Italian Atazanavir
Expanded Access Program and MASTER Cohorts.
Torti C, Lapadula G, Antinori A,
et al
Infection. 2009 May
26.
Abstract |
Iatrogenic Cushing's syndrome, diabetes mellitus and secondary adrenal
failure in a human immunodeficiency virus patient treated with ritonavir boosted
atazanavir and fluticasone.
Collet-Gaudillat C, Roussin-Bretagne S, Desforges-Bullet V,
et al
Ann Endocrinol (Paris).
2009 May 4.
Abstract
|
Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each
Administered in
Combination
with Zidovudine plus Lamivudine, in
Antiretroviral-Naive HIV-Infected Patients.
Jemsek JG, Arathoon E, Arlotti M, et al
Clin Infect Dis. 2006 Jan
15;42(2):273-80.
Abstract
|
Does atazanavir cause lipodystrophy?
Gazzard BG, Moyle G.
J HIV Ther. 2004 May;9(2):41-4
Abstract |
| |
Budget impact analysis of the simplification to atazanavir +
ritonavir + lamivudine dual therapy of HIV-positive patients receiving
atazanavir-based triple therapies in Italy starting from data of the Atlas-M
trial.
Restelli U, Fabbiani M, Di Giambenedetto S,
et al
Clinicoecon Outcomes Res.
2017 Mar 1;9:173-179
Abstract
Cost-effectiveness of atazanavir+ritonavir (ATV+RTV) vs.
lopinavir/ritonavir (LPV/r) in women of childbearing age in the United Kingdom.
Simpson K, Kirbach S,
Van de Steen O, Gooch K.
J
Int AIDS Soc. 2012 Nov
11;15(6):18385
Abstract
Cost effectiveness of atazanavir-ritonavir versus
lopinavir-ritonavir in treatment-naive human immunodeficiency virus-infected
patients in the United States.
Broder MS, Chang EY, Bentley TG, Juday T, Uy J.
J Med Econ.
2011 Feb 2.
Abstract
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in
treatment-naďve
human immunodeficiency virus-1 patients in Sweden.
Thuresson PO, Heeg B, Lescrauwaet B, et al
Scand J Infect Dis. 2011
Jan 13
Abstract |
|
| |
Inflammation
investigated as a source of pharmacokinetic variability of atazanavir in AIDS
Clinical Trials Group protocol A5224s.
Venuto CS, Lim J, Messing S,
et al
Antivir Ther. 2017 Nov 24.
Abstract
Race/ethnicity difference in the pharmacogenetics of bilirubin-related
atazanavir discontinuation.
Leger P, Chirwa S, Nwogu JN, et al
;
Pharmacogenet Genomics. 2017 Nov 6
Abstract
Pharmacogenetics of unboosted atazanavir in HIV-infected
individuals in resource-limited settings: a sub-study of the AIDS Clinical
Trials Group (ACTG) PEARLS study (NWCS 342).
Castillo-Mancilla JR, Aquilante CL, Wempe MF,
et al
J Antimicrob Chemother. 2016 Feb 17.
Abstract
Single-nucleotide polymorphisms in the
UDP-glucuronosyltransferase 1A-3' untranslated region are associated with
atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a
pharmacogenetic study.
Nishijima T, Tsuchiya K, Tanaka N,
et al
J Antimicrob Chemother. 2014 Aug 23.
Abstract
A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
Kile DA, Mawhinney S, Aquilante C,
et a
AIDS Res Hum Retroviruses. 2012
Mar 6
Abstract |
|
|
Atazanavir Journal Citations |
|
Atazanavir Main Page
Home
Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader